A PfRH5-based vaccine is efficacious against heterologous strain blood-stage plasmodium falciparum infection in Aotus monkeys

Cell Host and Microbe

Volumn 17, Issue 1, 2015, Pages 130-139

  Douglas, Alexander D ^a   Baldeviano, G Christian ^b   Lucas, Carmen M ^b   Lugo Roman, Luis A ^b   Crosnier, Cécile ^c   Bartholdson, S Josefin ^c   Diouf, Ababacar ^d   Miura, Kazutoyo ^d   Lambert, Lynn E ^d   Ventocilla, Julio A ^b   Leiva, Karina P ^b   Milne, Kathryn H ^a   Illingworth, Joseph J ^a   Spencer, Alexandra J ^a   Hjerrild, Kathryn A ^a   Alanine, Daniel G W ^a   Turner, Alison V ^a   Moorhead, Jeromy T ^b   Edgel, Kimberly A ^b   Wu, Yimin ^d   Long, Carole A ^d   Wright, Gavin J ^c   Lescano, Andrés G ^b   Draper, Simon J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b California   (Peru)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; NEUTRALIZING ANTIBODY; PARASITE ANTIBODY; PLASMODIUM FALCIPARUM RETICULOCYTE BINDING PROTEIN HOMOLOG 5; PLASMODIUM FALCIPARUM RETICULOCYTE BINDING PROTEIN HOMOLOG 5 ANTIBODY; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; CARRIER PROTEIN; PARASITE ANTIGEN; PROTOZOON ANTIBODY; RH5 PROTEIN, PLASMODIUM FALCIPARUM;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; ANTIMALARIAL ACTIVITY; AOTUS; ARTICLE; CELL INVASION; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE FUNCTION AND CHARACTERISTICS; ERYTHROCYTE INVASION; FEMALE; HETEROLOGOUS IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MEROZOITE; NONHUMAN; PARASITE VIRULENCE; PLASMODIUM (LIFE CYCLE STAGE); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VACCINATION; ANIMAL; BLOOD; DISEASE MODEL; IMMUNOLOGY; MALARIA; SERODIAGNOSIS;

AOTUS (PRIMATE); PLASMODIUM FALCIPARUM; PRIMATES;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; AOTUS TRIVIRGATUS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNITY, HETEROLOGOUS; MALARIA; MALARIA VACCINES; NEUTRALIZATION TESTS;

EID: 84920932154     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2014.11.017     Document Type: Article

References (60)

1. S.T. Agnandji, B. Lell, J.F. Fernandes, B.P. Abossolo, B.G. Methogo, A.L. Kabwende, A.A. Adegnika, B. Mordmüller, S. Issifou, P.G. Kremsner RTS,S Clinical Trials Partnership A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants N. Engl. J. Med. 367 2012 2284 2295
2. J. Baum, L. Chen, J. Healer, S. Lopaticki, M. Boyle, T. Triglia, F. Ehlgen, S.A. Ralph, J.G. Beeson, and A.F. Cowman Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum Int. J. Parasitol. 39 2009 371 380
3. S. Biswas, M.D. Dicks, C.A. Long, E.J. Remarque, L. Siani, S. Colloca, M.G. Cottingham, A.A. Holder, S.C. Gilbert, A.V. Hill, and S.J. Draper Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1 PLoS ONE 6 2011 e20977
4. S. Biswas, A.J. Spencer, E.K. Forbes, S.C. Gilbert, A.A. Holder, A.V. Hill, and S.J. Draper Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection J. Immunol. 188 2012 5041 5053
5. L.Y. Bustamante, S.J. Bartholdson, C. Crosnier, M.G. Campos, M. Wanaguru, C. Nguon, D.P. Kwiatkowski, G.J. Wright, and J.C. Rayner A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants Vaccine 31 2013 373 379
6. W.E. Collins, G.G. Galland, J.S. Sullivan, and C.L. Morris Selection of different strains of Plasmodium falciparum for testing blood-stage vaccines in Aotus nancymai monkeys Am. J. Trop. Med. Hyg. 51 1994 224 232
7. C. Crosnier, L.Y. Bustamante, S.J. Bartholdson, A.K. Bei, M. Theron, M. Uchikawa, S. Mboup, O. Ndir, D.P. Kwiatkowski, and M.T. Duraisingh Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum Nature 480 2011 534 537
8. C.A. Darko, E. Angov, W.E. Collins, E.S. Bergmann-Leitner, A.S. Girouard, S.L. Hitt, J.S. McBride, C.L. Diggs, A.A. Holder, and C.A. Long The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites Infect. Immun. 73 2005 287 297
9. S.C. de Cassan, and S.J. Draper Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets Expert Rev. Vaccines 12 2013 365 378
10. S.C. de Cassan, E.K. Forbes, A.D. Douglas, A. Milicic, B. Singh, P. Gupta, V.S. Chauhan, C.E. Chitnis, S.C. Gilbert, A.V. Hill, and S.J. Draper The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus J. Immunol. 187 2011 2602 2616
11. A.D. Douglas, A.R. Williams, J.J. Illingworth, G. Kamuyu, S. Biswas, A.L. Goodman, D.H. Wyllie, C. Crosnier, K. Miura, and G.J. Wright The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody Nat. Commun. 2 2011 601
12. A.D. Douglas, A.R. Williams, E. Knuepfer, J.J. Illingworth, J.M. Furze, C. Crosnier, P. Choudhary, L.Y. Bustamante, S.E. Zakutansky, and D.K. Awuah Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5 J. Immunol. 192 2014 245 258
13. S.J. Draper, and J.L. Heeney Viruses as vaccine vectors for infectious diseases and cancer Nat. Rev. Microbiol. 8 2010 62 73
14. S.J. Draper, A.C. Moore, A.L. Goodman, C.A. Long, A.A. Holder, S.C. Gilbert, F. Hill, and A.V. Hill Effective induction of high-titer antibodies by viral vector vaccines Nat. Med. 14 2008 819 821
15. S.J. Draper, S. Biswas, A.J. Spencer, E.J. Remarque, S. Capone, M. Naddeo, M.D.J. Dicks, B.W. Faber, S.C. de Cassan, and A. Folgori Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines J. Immunol. 185 2010 7583 7595
16. C.J. Duncan, A.V. Hill, and R.D. Ellis Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum. Vaccin. Immunother. 8 2012 706 714
17. Y. Durocher, S. Perret, and A. Kamen High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells Nucleic Acids Res. 30 2002 E9
18. S. Dutta, J.S. Sullivan, K.K. Grady, J.D. Haynes, J. Komisar, A.H. Batchelor, L. Soisson, C.L. Diggs, D.G. Heppner, and D.E. Lanar High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model PLoS ONE 4 2009 e8138
19. S.C. Elias, P. Choudhary, S.C. de Cassan, S. Biswas, K.A. Collins, F.D. Halstead, C.M. Bliss, K.J. Ewer, S.H. Hodgson, and C.J. Duncan Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection Immunology 141 2014 628 644
20. K.J. Ewer, G.A. O'Hara, C.J. Duncan, K.A. Collins, S.H. Sheehy, A. Reyes-Sandoval, A.L. Goodman, N.J. Edwards, S.C. Elias, and F.D. Halstead Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation Nat. Commun. 4 2013 2836
21. L. Foquet, C.C. Hermsen, G.J. van Gemert, E. Van Braeckel, K.E. Weening, R. Sauerwein, P. Meuleman, and G. Leroux-Roels Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection J. Clin. Invest. 124 2014 140 144
22. A.L. Goodman, and S.J. Draper Blood-stage malaria vaccines - recent progress and future challenges Ann. Trop. Med. Parasitol. 104 2010 189 211
23. A.L. Goodman, C. Epp, D. Moss, A.A. Holder, J.M. Wilson, G.P. Gao, C.A. Long, E.J. Remarque, A.W. Thomas, and V. Ammendola New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1 Infect. Immun. 78 2010 4601 4612
24. A.L. Goodman, E.K. Forbes, A.R. Williams, A.D. Douglas, S.C. de Cassan, K. Bauza, S. Biswas, M.D. Dicks, D. Llewellyn, and A.C. Moore The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment Sci Rep 3 2013 1706
25. S. Gupta, R.W. Snow, C.A. Donnelly, K. Marsh, and C. Newbold Immunity to non-cerebral severe malaria is acquired after one or two infections Nat. Med. 5 1999 340 343
26. K. Hayton, D. Gaur, A. Liu, J. Takahashi, B. Henschen, S. Singh, L. Lambert, T. Furuya, R. Bouttenot, and M. Doll Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion Cell Host Microbe 4 2008 40 51
27. K. Hayton, P. Dumoulin, B. Henschen, A. Liu, J. Papakrivos, and T.E. Wellems Various PfRH5 polymorphisms can support Plasmodium falciparum invasion into the erythrocytes of owl monkeys and rats Mol. Biochem. Parasitol. 187 2013 103 110
28. A.V. Hill Vaccines against malaria Philos. Trans. R. Soc. Lond. B Biol. Sci. 366 2011 2806 2814
29. H. Hisaeda, A. Saul, J.J. Reece, M.C. Kennedy, C.A. Long, L.H. Miller, and A.W. Stowers Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys J. Infect. Dis. 185 2002 657 664
30. S.H. Hodgson, P. Choudhary, S.C. Elias, K.H. Milne, T.W. Rampling, S. Biswas, I.D. Poulton, K. Miura, A.D. Douglas, and D.G. Alanine Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial Mol. Ther. 22 2014 2142 2154
31. T.R. Jones, D.L. Narum, A.S. Gozalo, J. Aguiar, S.R. Fuhrmann, H. Liang, J.D. Haynes, J.K. Moch, C. Lucas, and T. Luu Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen J. Infect. Dis. 183 2001 303 312
32. M.C. Kennedy, J. Wang, Y. Zhang, A.P. Miles, F. Chitsaz, A. Saul, C.A. Long, L.H. Miller, and A.W. Stowers In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response Infect. Immun. 70 2002 6948 6960
33. K.E. Kester, J.F. Cummings, O. Ofori-Anyinam, C.F. Ockenhouse, U. Krzych, P. Moris, R. Schwenk, R.A. Nielsen, Z. Debebe, E. Pinelis RTS,S Vaccine Evaluation Group Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection J. Infect. Dis. 200 2009 337 346
34. J.A. Lyon, E. Angov, M.P. Fay, J.S. Sullivan, A.S. Girourd, S.J. Robinson, E.S. Bergmann-Leitner, E.H. Duncan, C.A. Darko, and W.E. Collins Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses PLoS ONE 3 2008 e2830
35. M. Mahdi Abdel Hamid, E.J. Remarque, L.M. van Duivenvoorde, N. van der Werff, V. Walraven, B.W. Faber, C.H. Kocken, and A.W. Thomas Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques PLoS ONE 6 2011 e20547
36. M. Manske, O. Miotto, S. Campino, S. Auburn, J. Almagro-Garcia, G. Maslen, J. O'Brien, A. Djimde, O. Doumbo, and I. Zongo Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing Nature 487 2012 375 379
37. K. Miura, H. Zhou, A. Diouf, S.E. Moretz, M.P. Fay, L.H. Miller, L.B. Martin, M.A. Pierce, R.D. Ellis, G.E. Mullen, and C.A. Long Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay Clin. Vaccine Immunol. 16 2009 963 968
38. V.S. Moorthy, R.D. Newman, and J.M. Okwo-Bele Malaria vaccine technology roadmap Lancet 382 2013 1700 1701
39. C.J. Murray, L.C. Rosenfeld, S.S. Lim, K.G. Andrews, K.J. Foreman, D. Haring, N. Fullman, M. Naghavi, R. Lozano, and A.D. Lopez Global malaria mortality between 1980 and 2010: a systematic analysis Lancet 379 2012 413 431
40. L.M. Murungi, G. Kamuyu, B. Lowe, P. Bejon, M. Theisen, S.M. Kinyanjui, K. Marsh, and F.H. Osier A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria Vaccine 31 2013 3936 3942
41. S.D. Patel, A.D. Ahouidi, A.K. Bei, T.N. Dieye, S. Mboup, S.C. Harrison, and M.T. Duraisingh Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans J. Infect. Dis. 208 2013 1679 1687
42. S.A. Plotkin Correlates of protection induced by vaccination Clin. Vaccine Immunol. 17 2010 1055 1065
43. K.S. Reddy, A.K. Pandey, H. Singh, T. Sahar, A. Emmanuel, C.E. Chitnis, V.S. Chauhan, and D. Gaur Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies Infect. Immun. 82 2014 152 164
44. E.J. Remarque, B.W. Faber, C.H. Kocken, and A.W. Thomas Apical membrane antigen 1: a malaria vaccine candidate in review Trends Parasitol. 24 2008 74 84
45. E.M. Riley, and V.A. Stewart Immune mechanisms in malaria: new insights in vaccine development Nat. Med. 19 2013 168 178
46. S.H. Sheehy, C.J. Duncan, S.C. Elias, K.A. Collins, K.J. Ewer, A.J. Spencer, A.R. Williams, F.D. Halstead, S.E. Moretz, and K. Miura Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors Mol. Ther. 19 2011 2269 2276
47. S.H. Sheehy, C.J. Duncan, S.C. Elias, P. Choudhary, S. Biswas, F.D. Halstead, K.A. Collins, N.J. Edwards, A.D. Douglas, and N.A. Anagnostou ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans Mol. Ther. 20 2012 2355 2368
48. S.H. Sheehy, A.D. Douglas, and S.J. Draper Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines Hum. Vaccin. Immunother. 9 2013 1831 1840
49. S. Singh, K. Miura, H. Zhou, O. Muratova, B. Keegan, A. Miles, L.B. Martin, A.J. Saul, L.H. Miller, and C.A. Long Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity Infect. Immun. 74 2006 4573 4580
50. M.D. Spring, J.F. Cummings, C.F. Ockenhouse, S. Dutta, R. Reidler, E. Angov, E. Bergmann-Leitner, V.A. Stewart, S. Bittner, and L. Juompan Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A PLoS ONE 4 2009 e5254
51. A.W. Stowers, and L.H. Miller Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol. 17 2001 415 419
52. A.W. Stowers, V. Cioce, R.L. Shimp, M. Lawson, G. Hui, O. Muratova, D.C. Kaslow, R. Robinson, C.A. Long, and L.H. Miller Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial Infect. Immun. 69 2001 1536 1546
53. A.W. Stowers, M.C. Kennedy, B.P. Keegan, A. Saul, C.A. Long, and L.H. Miller Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria Infect. Immun. 70 2002 6961 6967
54. M.A. Thera, O.K. Doumbo, D. Coulibaly, M.B. Laurens, A. Ouattara, A.K. Kone, A.B. Guindo, K. Traore, I. Traore, and B. Kouriba A field trial to assess a blood-stage malaria vaccine N. Engl. J. Med. 365 2011 1004 1013
55. T.M. Tran, A. Ongoiba, J. Coursen, C. Crosnier, A. Diouf, C.Y. Huang, S. Li, S. Doumbo, D. Doumtabe, and Y. Kone Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria J. Infect. Dis. 209 2014 789 798
56. E. Villasis, M. Lopez-Perez, K. Torres, D. Gamboa, V. Neyra, J. Bendezu, N. Tricoche, C. Lobo, J.M. Vinetz, and S. Lustigman Anti-Plasmodium falciparum invasion ligand antibodies in a low malaria transmission region, Loreto, Peru Malar. J. 11 2012 361
57. M. Wanaguru, W. Liu, B.H. Hahn, J.C. Rayner, and G.J. Wright RH5-Basigin interaction plays a major role in the host tropism of Plasmodium falciparum Proc. Natl. Acad. Sci. USA 110 2013 20735 20740
58. W.R. Weiss, A. Kumar, G. Jiang, J. Williams, A. Bostick, S. Conteh, D. Fryauff, J. Aguiar, M. Singh, and D.T. O'Hagan Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens PLoS ONE 2 2007 e1063
59. A.R. Williams, A.D. Douglas, K. Miura, J.J. Illingworth, P. Choudhary, L.M. Murungi, J.M. Furze, A. Diouf, O. Miotto, and C. Crosnier Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens PLoS Pathog. 8 2012 e1002991
60. G.J. Wright, and J.C. Rayner Plasmodium falciparum erythrocyte invasion: combining function with immune evasion PLoS Pathog. 10 2014 e1003943